MedTrace Logo

A Study of IMR-687 in Subjects With Beta Thalassemia

NCT04411082 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Conditions

  • β Thalassemia

Interventions

DRUG

IMR-687

Oral administration of once daily IMR-687

DRUG

Placebo

Oral administration of once daily Placebo

Sponsors & Collaborators

  • Imara, Inc.

    collaborator INDUSTRY

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Luperchio · Cardurion Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-16
Primary Completion
2022-03-11
Completion
2022-05-04
FDA Drug
Yes

Countries

  • Denmark
  • France
  • Georgia
  • Greece
  • Israel
  • Italy
  • Lebanon
  • Malaysia
  • Morocco
  • Netherlands
  • Tunisia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411082 on ClinicalTrials.gov